SlideShare a Scribd company logo
PRESENTATION
ON
PARKINSON DISEASE
Presented by:
Baby Haokip
1st Year MSc (N)
Famous personalities with PD
INTRODUCTION:
 Parkinson disease is a slowly progressive , chronic
neurological disease that effects a small area of nerve cells in
an area of the brain known as the substantia nigra.
 This cells normally produces dopamine, a chemical
(neurotransmission) that transmits signal between areas in the
brain that when working normally coordinates smooth and
balanced muscle movement .
 Parkinson’s disease cause this nerve cells to die and as a result
body movement are effected.
HISTORYOF PD:
 In 1817, a detailed medical essay was published on the
subject by London doctor, Dr. James Parkinson.
 Jean Martin Charcot was the first to truly recognize the
importance of Dr. James Parkinson’s and renamed the
disease after him as ‘’Parkinson’s disease’’ which was
formerly named paralysis agitation (shaking palsy).
EPIDEMIOLOGY:
 Parkinson disease occurs worldwide and is present in all races.
 Males are more affected than females.
 Prevention of Parkinson disease increase with increasing age of 1% of person
from age 60.
 YOPD starts between 21 -40 years of age affecting 5 to 10% of Parkinson
disease patients.
 China is the country world largest prevalence of Parkinson disease.
 The incidence and prevalence of Parkinson disease in India is lesser as
compared to other country, Rural population had a higher prevalence than
urban population 41:14.
DEFINITION:
 Parkinson disease is characterized by
tremor at rest, rigidity and slowness
or difficulty in initiating and
executing movement (Akinesis or
Bradykinesis). This combination of
clinical features is collectively known
as Parkinsonism.
 Parkinsonism is a syndrome with
numerous cause of which Parkinson
disease is the most common.
ANATOMY
 The substantia nirga is a nucleus in the mid brain which is part of the Basal
Ganglia.
 The substantia nigra is made up of two automatically and functionally distinct
portion :
 Substantia nigra pars compacta –more darkened
 Substantia Nigra pars reticulata –less darken.
 Most of the dopamine neuron of the brain originate in the midbrain and are
found in either the substantia Nigra.
 The Dopamine neurons in the substantia Nigra express high level of pigment
called Neuromelanin which accounts for thin dark colour .
 The substantia Nigra par compacta contain more dopamine neurons while pars
Reticulate contains more GABA neurons .
CLINICAL SIGNIFICANCE:
 Parkinson disease is associated with the
death of dopamine Neuron in the
substantia Nigra pars compacta which is
due to neuro-degeneration .
 when a significant number of this neuron
have died, the individual will likely to
start to experienced movement –related
problems like tremors, rigidity, slowness
of movement and postural instability –
which are the hall mark symptoms of
Parkinson disease.
ETIOLOGY/RISK FACTORS:
 Advancing age : Above 60 years mostly seen while young onset Parkinson disease
is called a patients develop Parkinson disease between 21-40 years.
 Sex: male are more likely to get than female.
 Family History: Having one or more close relatives with the disease increase the
rise of getting.
 Low Estrogen Level: most menopausal women who don’t use hormone
replacement therapy are more risk of getting the disease.
 Agricultural work: exposure to environmental toxin such as pesticide ,herbicides
,inhabits dopamine production and promote free radical damage. these involved
in farming and are exposed to such toxins have a greater risk of getting the
disease.
 Low level of vitamins: researchers de was found that people with low level of
vitamin B develop severe Parkinson symptoms.
 Head Trauma: Trauma to the head ,neck and upper cervical spine increase the
chance of getting Parkinson’s.
Genetic Mutation: people who have both young onset Parkinson’s disease and a
strong family history of the disease are more likely carry genes linked to
Parkinson’s disease which includes;
 Alpha Synuclein: Autosomal dominant.
 LRRK2(leucine rich repeat kinesis2): Autosomal.
 PINK1/PARKIN/DJ-1: Autosomal recessive
 GBA(Glucocerebrocidase): Autosomal recessive
 Alpha synuclein and LRRK2 gene mutation is linked with Young onset Parkinson
Disease.
Other causes:
 Secondary Parkinson’s: which are caused by other disorders such as
Neoplasm, multiple cerebral infarction and infection of the brain.
 Drug induces Parkinsonism: which are irreversible. causative drugs
include : Neuroleptics – haloperidol ,risperidone, olanzapine.
Antiemetic- metachlopramine, prochlorperazine.
 Parkinson’s disease caused by Degenerative disease in which
symptoms of Parkinson’s disease are combines with neurologic deficit
yet patients fail to response to Anti-Parkinson drugs therapy . These
disorders include
 Multiple system atrophy (MSA).
 Alzheimer’s Disease -often accompanied with mild signs of
Parkinsonism.
PATHOPHYSIOLOGY:
Etiological Factors:
 Environmental
factors
 Gene mutation
 Degenerative
disease
Destruction of Dopaminergic neuronal cells in the substantia nigra in the
basal Ganglia
Neuronal cells loss and depigmentation
Degeneration of dopaminergic activity particularly in the nigro-striatal
pathway
Depletion of dopamine store
Imbalance between excitatory (Acetylcholine) and inhibiting
(dopamine) neurotransmitter in the corpus striation
Impairment of extrapyramidal tract controlling
complex body movement
Tremors
Rigidity
Akinesis
Postural instability
SIGNS AND SYMPTOMS:
Four cardinal sign:
 Resting tremor
 Rigidity
 Akinesia
 Postural instability
Cog-wheeling
AKINESIA:
Bradykinesia
Hypokinesia
Hypophonia
Micrographia
DYSAUTONOMIA: it includes
 sweats,facial flushing.
 Dyspnea, urinary frequency, urgency.
 GI dysfunction-constipation.
 Dysphagia
 Orthostatic hypotension and sexual
dysfunction
Cognitive And psychiatric disturbance:
Anxiety, Apathy, mental, irritability,
impaired executive function, depression
psychosis (delusions and Italicization)
dementia
 POSTURAL DISTURBANCE:
Stooped or fixed positive
 Disequilibrium or postural
instability
 Retropulsion –backward
motion
 Propulsion – forward motion
Sleep disturbance:
Frequent awakening
Daytimes sleepiness’
Sensory impairment:
pain, restlessness and
Akathisia.
STAGES OF PARKINSON’s DISEASE
 Parkinson’s disease is typically classified by the worsenng of clinical
manifestation. The modified Hoehn and yohr and scale is one method use to
rate the severity of Parkinson’s disease.
 STAGE 0: No evidence of Parkinson’s disease.
 Stage 1: Unilateral involvement .
 Stage 1.5: Unilateral and Axial involvement .
 Stage 2: Bilateral involvement, balance in contact .
 Stage 2.5: Bilateral involvement, recovery on pull test .
 Stage 3: Mild to moderate impairment with postural instability .
 Stage 4: Severe impairment but still able to stand or walk un assisted.
 Stages 5: Confinement to a wheel chair or bed .
DIAGNOSTIC EVALUATION:
 Laboratory test and imaging studies are not helpful in the diagnosis of
Parkinson’s disease.
 Criteria for making diagnosis of Parkinson’s disease include the
following
1. Through patients’ history and performed complete neurological
examination.
2. CT scan or MRI of head to rule out secondary cause.
3. PET-scan to evaluate levodopa uptake and conversion to Dopamine in
the corpus Striatum .
4. Present of two or more cardinal features (resting tremors, rigidity,
Akinesia, postural instability).
5.Final diagnosis usually made by the pressure of heavy bodies in the
brain during Autopsy.
MANAGEMENT:
 There are complete cure for Parkinson’s disease.
 Treatment is directed at controlling symptoms and maintaining
functional independence.
 There are no medical or surgical approaches that prevent
disease progression.
 Care is individualized for each patients based on preventing
symptoms and social occupational and social needs.
 Pharmacologic management is the main stay of treatment.
ANTI-PARKINSONISM MEDICATION:
1. LEVEDOPA (L-Dopa): it is the most effective agents and the mainstay of treatment, for
controlling the symptoms particularly Bradykinesia and rigidity.
 SINEMET: it is made up of Levodopa and carbidopa .Levodopa enters the brain and is
converted to Dopamine while carbidopa increase its effectiveness and prevents the side
effects of levodopa such as nausea, vomiting.
2. DOPAMINE RECEPTOR AGONISTS: this are the drugs that activate or stimulate the
dopamine receptors . They mimic or copy the function of Dopamine in the brain. Dopamine
agonists can be taken alone or in combination with Levodopa/carbidopa. Most commonly
drugs used are
 Ergot derivatives : Bromocriptine or pergolite.
 Non-ergot Derivatives: Ropinirole ,pramipexole.
3. MONOAMINE OXIDIZED INHIBITORS: It blocks an enzymes that caused premature of
levodopa and are used primarily to treat motors fluctuation associated with levodopa
treatment .most commonly drugs used are
 Seligiline
 Rosagiline.
AMANTADINE : it is the most commonly used medication for early onset Parkinson’s
disease to tract tremor .It reduce dyskinesia’s that occur with Levodopa.
COMT INHIBITORS(Catechol-o-methyl-transferase): such is Tolcapone and entacapone
response the newest class of Parkinson’s drugs .
 It does not have direct effect on Parkinson’s disease symptoms
 it prolong the effect of levodopa by blocking its metabolism.
ANTI-CHOLINERGIC: it is helpful in controlling tremors and rigidity.
 It decrease the activity of acetylcholine, a neurotransmitter that regulates
movement ,most commonly used are:
 Benzotropine mesylate
 Trihexyphenidyl HCL
ANTI-DEPRESSANT :
 Amitriptyline is typically prescribe because of its Anticholinergic and
Antidepressant effect.
 Serotonins reuptake inhibitors; Fluoxetine Hydrochloride and Bupropion
hydrochloride.
 Effective for treating depression in patients with Parkinson’s disease.
SURGICAL MANAGEMENT:
THALATOMY:
 It involves destruction of part of the Thalamus,
generally the ventral’s intermediates (VIM) to
relieve tremor.
 The VIM nucleus is considered the best target for
tremor suppression with excellent short and long
term tremor suppression in 80-90% of patients
with Parkinson’s diseases.
 When rigidity and Akinesia are prominent other
targets ,deep brain stimulation of both Globus
pallidus interna (Gpi) and subthalami nucleus
(STN)are preferred.
PALLIDOTOMY:
 Pallidotomy is a neurosurgical
procedure whereby a tiny electrical
probe is placed in the globes pallidus,
which is then heated to 800C for 60
sec, to destroy a small area of brain
cells.
 It is effective for treating in
voluntary movements known as
Dyskinesia, motor symptoms
presented with Parkinson’s Disease.
DEEP BRAIN STIMULATION:
 Deep brain stimulation is a neurological procedure
which was first approved in 1997 to treat Parkinson’s
diseases tremor, then in 2002 for treatment of
advanced Parkinson’s diseases symptoms.
 More recently in 2016 DBS surgery was approved for
the earlier stages of Parkinson’s for those with at least
four years disease duration with motors complication
that are not controlled with medications.
 Deep brain stimulation involves the implantation of
permanents thin electrodes into selected deep parts
of the brain .
 The targets area of the brain depends on the
presenting symptoms, the most common targets area
are thalamus, subthalamic nucleus(STN)and Globus
pallidus in terna(Gpi).
NURSING MANAGEMENT:
Nursing Assessment:
 Obtain a history of symptoms and their effect on functioning,
mobility, feeding, communication, and self-care difficulties.
 Assess cranial nerves, cerebellar function (co-ordination) and
motor function.
 Observe gait and performance of activities
 Assess speech for clarity and space
 Assess for sign of depression
 Assess family supports and access to social service.
Nursing Diagnosis:
1. Impaired physical mobility related to Bradykinesia,
rigidity and tremors
2. Imbalance nutrition less than body requirement related
to motor difficulties with feeding, chewing and swallowing
3. Impaired verbal communication related to decreased
speech volume
4. Constipation related to diminished motor function and
inactivity
5. Ineffective coping related to physical limitation and loss
of independence.
CONCLUSION:
 Parkinson’s disease is a chronic, progressive neurologic disorders that results
from the loss of the neurotransmitter dopamine in a group of brain structures
that controls movement.
 The cardinal symptoms are resting tremors, rigidity, Akinesia and postural
instability.
 The goal of management is to control the manifestation such as motor and
non-motor symptoms with the lowest possible dose of medication in order to
avoid side effects.
 Medication selection and dosage depend on the manifestation, age of the
client and presence of other medical condition.
 Nursing care should focus on the health assessment, medication instruction
and monitoring, liaison with other members of the health care team, and
family members and family education.
pksonsds-180320161607.pdf

More Related Content

Similar to pksonsds-180320161607.pdf

barkinson's disease
barkinson's diseasebarkinson's disease
barkinson's disease
Sadiiq Cabdi
 
Parkinsons disease V Pharm.D
Parkinsons disease V Pharm.DParkinsons disease V Pharm.D
Parkinsons disease V Pharm.D
Dr.Sohel Memon
 
Parkinson's disease
 Parkinson's disease Parkinson's disease
Parkinson's disease
Sunil Pahari
 
Advances in Management of Parkinson's Disease
Advances in Management of Parkinson's DiseaseAdvances in Management of Parkinson's Disease
Advances in Management of Parkinson's Disease
Sultana Shaikh
 
Aposan-Scientific information.pptx
Aposan-Scientific information.pptxAposan-Scientific information.pptx
Aposan-Scientific information.pptx
LakshyaJBasumatary
 
Neuro parkinsonism
Neuro parkinsonismNeuro parkinsonism
Neuro parkinsonism
Meghana Nadendla
 
Presentation1.pptx
Presentation1.pptxPresentation1.pptx
Presentation1.pptx
ssuserb0ac5f
 
Antiparkinson's Drugs
Antiparkinson's DrugsAntiparkinson's Drugs
Antiparkinson's Drugs
Bhudev Global
 
Parkinson’s Disease .pptx
Parkinson’s Disease                .pptxParkinson’s Disease                .pptx
Parkinson’s Disease .pptx
DianneSablayan1
 
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
Soujanya Pharm.D
 
Pharmacology - Parkinsonism
Pharmacology - ParkinsonismPharmacology - Parkinsonism
Pharmacology - Parkinsonism
MBBS IMS MSU
 
Parkinsons disease
Parkinsons diseaseParkinsons disease
Parkinsons disease
Bhupendra Shah
 
Pharmacotherapy of Parkinson's Disease
Pharmacotherapy of Parkinson's DiseasePharmacotherapy of Parkinson's Disease
Pharmacotherapy of Parkinson's Disease
Koppala RVS Chaitanya
 
Parkinson’s disease
Parkinson’s diseaseParkinson’s disease
Parkinson’s disease
Venkat Ashok Kothapalli
 
PARKINSON'S DISEASE PATHOPHYSIOLOGY B.PHARM 2ND SEM.pptx
PARKINSON'S DISEASE PATHOPHYSIOLOGY B.PHARM 2ND SEM.pptxPARKINSON'S DISEASE PATHOPHYSIOLOGY B.PHARM 2ND SEM.pptx
PARKINSON'S DISEASE PATHOPHYSIOLOGY B.PHARM 2ND SEM.pptx
subham404717
 
Parkinsons megan raven_phm1810
Parkinsons megan raven_phm1810Parkinsons megan raven_phm1810
Parkinsons megan raven_phm1810
meganrenee0291
 
PARKINSON’S DISEASE.pptx
PARKINSON’S DISEASE.pptxPARKINSON’S DISEASE.pptx
PARKINSON’S DISEASE.pptx
Ameena Kadar
 
Dissertation work ppt
Dissertation work pptDissertation work ppt
Dissertation work ppt
Mandara V M
 
Parkinson Disease
Parkinson DiseaseParkinson Disease
Parkinson Disease
AmiteshNawal
 
Parkinson's Disease
Parkinson's DiseaseParkinson's Disease
Parkinson's Disease
Sandra saju
 

Similar to pksonsds-180320161607.pdf (20)

barkinson's disease
barkinson's diseasebarkinson's disease
barkinson's disease
 
Parkinsons disease V Pharm.D
Parkinsons disease V Pharm.DParkinsons disease V Pharm.D
Parkinsons disease V Pharm.D
 
Parkinson's disease
 Parkinson's disease Parkinson's disease
Parkinson's disease
 
Advances in Management of Parkinson's Disease
Advances in Management of Parkinson's DiseaseAdvances in Management of Parkinson's Disease
Advances in Management of Parkinson's Disease
 
Aposan-Scientific information.pptx
Aposan-Scientific information.pptxAposan-Scientific information.pptx
Aposan-Scientific information.pptx
 
Neuro parkinsonism
Neuro parkinsonismNeuro parkinsonism
Neuro parkinsonism
 
Presentation1.pptx
Presentation1.pptxPresentation1.pptx
Presentation1.pptx
 
Antiparkinson's Drugs
Antiparkinson's DrugsAntiparkinson's Drugs
Antiparkinson's Drugs
 
Parkinson’s Disease .pptx
Parkinson’s Disease                .pptxParkinson’s Disease                .pptx
Parkinson’s Disease .pptx
 
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
 
Pharmacology - Parkinsonism
Pharmacology - ParkinsonismPharmacology - Parkinsonism
Pharmacology - Parkinsonism
 
Parkinsons disease
Parkinsons diseaseParkinsons disease
Parkinsons disease
 
Pharmacotherapy of Parkinson's Disease
Pharmacotherapy of Parkinson's DiseasePharmacotherapy of Parkinson's Disease
Pharmacotherapy of Parkinson's Disease
 
Parkinson’s disease
Parkinson’s diseaseParkinson’s disease
Parkinson’s disease
 
PARKINSON'S DISEASE PATHOPHYSIOLOGY B.PHARM 2ND SEM.pptx
PARKINSON'S DISEASE PATHOPHYSIOLOGY B.PHARM 2ND SEM.pptxPARKINSON'S DISEASE PATHOPHYSIOLOGY B.PHARM 2ND SEM.pptx
PARKINSON'S DISEASE PATHOPHYSIOLOGY B.PHARM 2ND SEM.pptx
 
Parkinsons megan raven_phm1810
Parkinsons megan raven_phm1810Parkinsons megan raven_phm1810
Parkinsons megan raven_phm1810
 
PARKINSON’S DISEASE.pptx
PARKINSON’S DISEASE.pptxPARKINSON’S DISEASE.pptx
PARKINSON’S DISEASE.pptx
 
Dissertation work ppt
Dissertation work pptDissertation work ppt
Dissertation work ppt
 
Parkinson Disease
Parkinson DiseaseParkinson Disease
Parkinson Disease
 
Parkinson's Disease
Parkinson's DiseaseParkinson's Disease
Parkinson's Disease
 

Recently uploaded

Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
Gokuldas Hospital
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
MedicoseAcademics
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
Torstein Dalen-Lorentsen
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
19various
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
Jim Jacob Roy
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
ZayedKhan38
 
10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations   10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations
Traumasoft LLC
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
AksshayaRajanbabu
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Kanhu Charan
 

Recently uploaded (20)

Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
 
10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations   10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
 

pksonsds-180320161607.pdf

  • 3. INTRODUCTION:  Parkinson disease is a slowly progressive , chronic neurological disease that effects a small area of nerve cells in an area of the brain known as the substantia nigra.  This cells normally produces dopamine, a chemical (neurotransmission) that transmits signal between areas in the brain that when working normally coordinates smooth and balanced muscle movement .  Parkinson’s disease cause this nerve cells to die and as a result body movement are effected.
  • 4. HISTORYOF PD:  In 1817, a detailed medical essay was published on the subject by London doctor, Dr. James Parkinson.  Jean Martin Charcot was the first to truly recognize the importance of Dr. James Parkinson’s and renamed the disease after him as ‘’Parkinson’s disease’’ which was formerly named paralysis agitation (shaking palsy).
  • 5. EPIDEMIOLOGY:  Parkinson disease occurs worldwide and is present in all races.  Males are more affected than females.  Prevention of Parkinson disease increase with increasing age of 1% of person from age 60.  YOPD starts between 21 -40 years of age affecting 5 to 10% of Parkinson disease patients.  China is the country world largest prevalence of Parkinson disease.  The incidence and prevalence of Parkinson disease in India is lesser as compared to other country, Rural population had a higher prevalence than urban population 41:14.
  • 6. DEFINITION:  Parkinson disease is characterized by tremor at rest, rigidity and slowness or difficulty in initiating and executing movement (Akinesis or Bradykinesis). This combination of clinical features is collectively known as Parkinsonism.  Parkinsonism is a syndrome with numerous cause of which Parkinson disease is the most common.
  • 8.  The substantia nirga is a nucleus in the mid brain which is part of the Basal Ganglia.  The substantia nigra is made up of two automatically and functionally distinct portion :  Substantia nigra pars compacta –more darkened  Substantia Nigra pars reticulata –less darken.  Most of the dopamine neuron of the brain originate in the midbrain and are found in either the substantia Nigra.  The Dopamine neurons in the substantia Nigra express high level of pigment called Neuromelanin which accounts for thin dark colour .  The substantia Nigra par compacta contain more dopamine neurons while pars Reticulate contains more GABA neurons .
  • 9. CLINICAL SIGNIFICANCE:  Parkinson disease is associated with the death of dopamine Neuron in the substantia Nigra pars compacta which is due to neuro-degeneration .  when a significant number of this neuron have died, the individual will likely to start to experienced movement –related problems like tremors, rigidity, slowness of movement and postural instability – which are the hall mark symptoms of Parkinson disease.
  • 10. ETIOLOGY/RISK FACTORS:  Advancing age : Above 60 years mostly seen while young onset Parkinson disease is called a patients develop Parkinson disease between 21-40 years.  Sex: male are more likely to get than female.  Family History: Having one or more close relatives with the disease increase the rise of getting.  Low Estrogen Level: most menopausal women who don’t use hormone replacement therapy are more risk of getting the disease.  Agricultural work: exposure to environmental toxin such as pesticide ,herbicides ,inhabits dopamine production and promote free radical damage. these involved in farming and are exposed to such toxins have a greater risk of getting the disease.  Low level of vitamins: researchers de was found that people with low level of vitamin B develop severe Parkinson symptoms.  Head Trauma: Trauma to the head ,neck and upper cervical spine increase the chance of getting Parkinson’s.
  • 11. Genetic Mutation: people who have both young onset Parkinson’s disease and a strong family history of the disease are more likely carry genes linked to Parkinson’s disease which includes;  Alpha Synuclein: Autosomal dominant.  LRRK2(leucine rich repeat kinesis2): Autosomal.  PINK1/PARKIN/DJ-1: Autosomal recessive  GBA(Glucocerebrocidase): Autosomal recessive  Alpha synuclein and LRRK2 gene mutation is linked with Young onset Parkinson Disease.
  • 12. Other causes:  Secondary Parkinson’s: which are caused by other disorders such as Neoplasm, multiple cerebral infarction and infection of the brain.  Drug induces Parkinsonism: which are irreversible. causative drugs include : Neuroleptics – haloperidol ,risperidone, olanzapine. Antiemetic- metachlopramine, prochlorperazine.  Parkinson’s disease caused by Degenerative disease in which symptoms of Parkinson’s disease are combines with neurologic deficit yet patients fail to response to Anti-Parkinson drugs therapy . These disorders include  Multiple system atrophy (MSA).  Alzheimer’s Disease -often accompanied with mild signs of Parkinsonism.
  • 13. PATHOPHYSIOLOGY: Etiological Factors:  Environmental factors  Gene mutation  Degenerative disease Destruction of Dopaminergic neuronal cells in the substantia nigra in the basal Ganglia Neuronal cells loss and depigmentation Degeneration of dopaminergic activity particularly in the nigro-striatal pathway Depletion of dopamine store Imbalance between excitatory (Acetylcholine) and inhibiting (dopamine) neurotransmitter in the corpus striation Impairment of extrapyramidal tract controlling complex body movement Tremors Rigidity Akinesis Postural instability
  • 14. SIGNS AND SYMPTOMS: Four cardinal sign:  Resting tremor  Rigidity  Akinesia  Postural instability Cog-wheeling AKINESIA: Bradykinesia Hypokinesia Hypophonia Micrographia DYSAUTONOMIA: it includes  sweats,facial flushing.  Dyspnea, urinary frequency, urgency.  GI dysfunction-constipation.  Dysphagia  Orthostatic hypotension and sexual dysfunction Cognitive And psychiatric disturbance: Anxiety, Apathy, mental, irritability, impaired executive function, depression psychosis (delusions and Italicization) dementia  POSTURAL DISTURBANCE: Stooped or fixed positive  Disequilibrium or postural instability  Retropulsion –backward motion  Propulsion – forward motion Sleep disturbance: Frequent awakening Daytimes sleepiness’ Sensory impairment: pain, restlessness and Akathisia.
  • 15. STAGES OF PARKINSON’s DISEASE  Parkinson’s disease is typically classified by the worsenng of clinical manifestation. The modified Hoehn and yohr and scale is one method use to rate the severity of Parkinson’s disease.  STAGE 0: No evidence of Parkinson’s disease.  Stage 1: Unilateral involvement .  Stage 1.5: Unilateral and Axial involvement .  Stage 2: Bilateral involvement, balance in contact .  Stage 2.5: Bilateral involvement, recovery on pull test .  Stage 3: Mild to moderate impairment with postural instability .  Stage 4: Severe impairment but still able to stand or walk un assisted.  Stages 5: Confinement to a wheel chair or bed .
  • 16. DIAGNOSTIC EVALUATION:  Laboratory test and imaging studies are not helpful in the diagnosis of Parkinson’s disease.  Criteria for making diagnosis of Parkinson’s disease include the following 1. Through patients’ history and performed complete neurological examination. 2. CT scan or MRI of head to rule out secondary cause. 3. PET-scan to evaluate levodopa uptake and conversion to Dopamine in the corpus Striatum . 4. Present of two or more cardinal features (resting tremors, rigidity, Akinesia, postural instability). 5.Final diagnosis usually made by the pressure of heavy bodies in the brain during Autopsy.
  • 17. MANAGEMENT:  There are complete cure for Parkinson’s disease.  Treatment is directed at controlling symptoms and maintaining functional independence.  There are no medical or surgical approaches that prevent disease progression.  Care is individualized for each patients based on preventing symptoms and social occupational and social needs.  Pharmacologic management is the main stay of treatment.
  • 18. ANTI-PARKINSONISM MEDICATION: 1. LEVEDOPA (L-Dopa): it is the most effective agents and the mainstay of treatment, for controlling the symptoms particularly Bradykinesia and rigidity.  SINEMET: it is made up of Levodopa and carbidopa .Levodopa enters the brain and is converted to Dopamine while carbidopa increase its effectiveness and prevents the side effects of levodopa such as nausea, vomiting. 2. DOPAMINE RECEPTOR AGONISTS: this are the drugs that activate or stimulate the dopamine receptors . They mimic or copy the function of Dopamine in the brain. Dopamine agonists can be taken alone or in combination with Levodopa/carbidopa. Most commonly drugs used are  Ergot derivatives : Bromocriptine or pergolite.  Non-ergot Derivatives: Ropinirole ,pramipexole. 3. MONOAMINE OXIDIZED INHIBITORS: It blocks an enzymes that caused premature of levodopa and are used primarily to treat motors fluctuation associated with levodopa treatment .most commonly drugs used are  Seligiline  Rosagiline.
  • 19. AMANTADINE : it is the most commonly used medication for early onset Parkinson’s disease to tract tremor .It reduce dyskinesia’s that occur with Levodopa. COMT INHIBITORS(Catechol-o-methyl-transferase): such is Tolcapone and entacapone response the newest class of Parkinson’s drugs .  It does not have direct effect on Parkinson’s disease symptoms  it prolong the effect of levodopa by blocking its metabolism. ANTI-CHOLINERGIC: it is helpful in controlling tremors and rigidity.  It decrease the activity of acetylcholine, a neurotransmitter that regulates movement ,most commonly used are:  Benzotropine mesylate  Trihexyphenidyl HCL ANTI-DEPRESSANT :  Amitriptyline is typically prescribe because of its Anticholinergic and Antidepressant effect.  Serotonins reuptake inhibitors; Fluoxetine Hydrochloride and Bupropion hydrochloride.  Effective for treating depression in patients with Parkinson’s disease.
  • 20. SURGICAL MANAGEMENT: THALATOMY:  It involves destruction of part of the Thalamus, generally the ventral’s intermediates (VIM) to relieve tremor.  The VIM nucleus is considered the best target for tremor suppression with excellent short and long term tremor suppression in 80-90% of patients with Parkinson’s diseases.  When rigidity and Akinesia are prominent other targets ,deep brain stimulation of both Globus pallidus interna (Gpi) and subthalami nucleus (STN)are preferred.
  • 21. PALLIDOTOMY:  Pallidotomy is a neurosurgical procedure whereby a tiny electrical probe is placed in the globes pallidus, which is then heated to 800C for 60 sec, to destroy a small area of brain cells.  It is effective for treating in voluntary movements known as Dyskinesia, motor symptoms presented with Parkinson’s Disease.
  • 22. DEEP BRAIN STIMULATION:  Deep brain stimulation is a neurological procedure which was first approved in 1997 to treat Parkinson’s diseases tremor, then in 2002 for treatment of advanced Parkinson’s diseases symptoms.  More recently in 2016 DBS surgery was approved for the earlier stages of Parkinson’s for those with at least four years disease duration with motors complication that are not controlled with medications.  Deep brain stimulation involves the implantation of permanents thin electrodes into selected deep parts of the brain .  The targets area of the brain depends on the presenting symptoms, the most common targets area are thalamus, subthalamic nucleus(STN)and Globus pallidus in terna(Gpi).
  • 23. NURSING MANAGEMENT: Nursing Assessment:  Obtain a history of symptoms and their effect on functioning, mobility, feeding, communication, and self-care difficulties.  Assess cranial nerves, cerebellar function (co-ordination) and motor function.  Observe gait and performance of activities  Assess speech for clarity and space  Assess for sign of depression  Assess family supports and access to social service.
  • 24. Nursing Diagnosis: 1. Impaired physical mobility related to Bradykinesia, rigidity and tremors 2. Imbalance nutrition less than body requirement related to motor difficulties with feeding, chewing and swallowing 3. Impaired verbal communication related to decreased speech volume 4. Constipation related to diminished motor function and inactivity 5. Ineffective coping related to physical limitation and loss of independence.
  • 25.
  • 26. CONCLUSION:  Parkinson’s disease is a chronic, progressive neurologic disorders that results from the loss of the neurotransmitter dopamine in a group of brain structures that controls movement.  The cardinal symptoms are resting tremors, rigidity, Akinesia and postural instability.  The goal of management is to control the manifestation such as motor and non-motor symptoms with the lowest possible dose of medication in order to avoid side effects.  Medication selection and dosage depend on the manifestation, age of the client and presence of other medical condition.  Nursing care should focus on the health assessment, medication instruction and monitoring, liaison with other members of the health care team, and family members and family education.